See more : Denkyo Group Holdings Co.,Ltd. (8144.T) Income Statement Analysis – Financial Results
Complete financial analysis of Avanos Medical, Inc. (AVNS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Avanos Medical, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Shanghai Maling Aquarius Co.,Ltd (600073.SS) Income Statement Analysis – Financial Results
- argenx SE (ARGX) Income Statement Analysis – Financial Results
- Atento S.A. (ATTOF) Income Statement Analysis – Financial Results
- Tesla, Inc. (TSLA) Income Statement Analysis – Financial Results
- Devin Energy Corporation (DVNGF) Income Statement Analysis – Financial Results
Avanos Medical, Inc. (AVNS)
About Avanos Medical, Inc.
Avanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 673.30M | 820.00M | 744.60M | 714.80M | 697.60M | 652.30M | 611.60M | 1.59B | 1.57B | 1.67B | 1.68B | 1.68B | 1.66B |
| Cost of Revenue | 293.60M | 370.00M | 380.30M | 341.50M | 295.40M | 261.40M | 274.70M | 1.03B | 1.04B | 1.12B | 1.07B | 1.08B | 1.07B |
| Gross Profit | 379.70M | 450.00M | 364.30M | 373.30M | 402.20M | 390.90M | 336.90M | 557.90M | 531.60M | 548.60M | 612.20M | 602.50M | 590.80M |
| Gross Profit Ratio | 56.39% | 54.88% | 48.93% | 52.22% | 57.65% | 59.93% | 55.09% | 35.04% | 33.77% | 32.81% | 36.49% | 35.78% | 35.59% |
| Research & Development | 27.20M | 30.60M | 32.30M | 34.90M | 37.70M | 41.80M | 38.20M | 41.10M | 32.30M | 33.60M | 37.90M | 33.00M | 31.20M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 340.40M | 321.70M | 411.10M | 398.50M | 424.50M | 351.40M | 343.00M | 351.70M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 318.10M | 341.90M | 300.30M | 332.60M | 399.10M | 340.40M | 321.70M | 411.10M | 398.50M | 424.50M | 351.40M | 343.00M | 351.70M |
| Other Expenses | 0.00 | 3.50M | 22.80M | 51.90M | 21.10M | 8.20M | 20.10M | 18.30M | 4.50M | -3.80M | -2.40M | -1.50M | -2.80M |
| Operating Expenses | 375.50M | 376.00M | 355.40M | 419.40M | 457.90M | 390.40M | 380.00M | 470.50M | 435.30M | 454.30M | 386.90M | 374.50M | 380.10M |
| Cost & Expenses | 669.10M | 746.00M | 735.70M | 760.90M | 753.30M | 651.80M | 654.70M | 1.50B | 1.48B | 1.58B | 1.45B | 1.46B | 1.45B |
| Interest Income | 2.90M | 1.20M | 200.00K | 1.20M | 6.70M | 7.80M | 2.50M | 600.00K | 300.00K | 2.90M | 2.60M | 2.60M | 4.10M |
| Interest Expense | 15.00M | 10.00M | 3.30M | 15.60M | 15.00M | 26.40M | 31.60M | 32.70M | 33.10M | 6.00M | 100.00K | 800.00K | 200.00K |
| Depreciation & Amortization | 46.10M | 41.10M | 38.30M | 42.90M | 36.90M | 33.50M | 40.00M | 41.00M | 65.40M | 85.40M | 69.20M | 57.60M | 51.10M |
| EBITDA | 50.60M | 77.80M | 8.90M | -2.00M | -12.10M | 65.70M | -600.00K | -65.50M | -76.50M | 179.70M | 297.10M | 288.20M | 265.90M |
| EBITDA Ratio | 7.52% | 14.99% | 6.37% | -0.28% | -1.73% | 6.41% | 3.09% | 9.62% | 10.29% | 10.92% | 17.71% | 17.11% | 16.02% |
| Operating Income | 4.20M | 74.00M | 8.90M | -46.10M | -55.70M | 500.00K | -43.10M | 87.40M | -377.70M | 94.30M | 225.30M | 228.00M | 210.70M |
| Operating Income Ratio | 0.62% | 9.02% | 1.20% | -6.45% | -7.98% | 0.08% | -7.05% | 5.49% | -23.99% | 5.64% | 13.43% | 13.54% | 12.69% |
| Total Other Income/Expenses | -12.10M | -8.80M | 44.80M | -14.40M | -8.30M | -18.60M | -29.10M | -32.10M | -274.80M | -3.10M | 2.50M | 1.80M | 3.90M |
| Income Before Tax | -7.90M | 65.20M | 5.80M | -60.50M | -64.00M | -18.10M | -72.20M | 55.30M | -410.50M | 91.20M | 227.80M | 229.80M | 214.60M |
| Income Before Tax Ratio | -1.17% | 7.95% | 0.78% | -8.46% | -9.17% | -2.77% | -11.81% | 3.47% | -26.07% | 5.45% | 13.58% | 13.65% | 12.93% |
| Income Tax Expense | 2.00M | 14.70M | 600.00K | -33.30M | -18.10M | -9.60M | -40.10M | 15.50M | 15.80M | 64.10M | 73.20M | 77.20M | 72.20M |
| Net Income | -61.80M | 50.50M | 6.30M | -27.20M | -45.90M | 57.50M | 79.30M | 39.80M | -426.30M | 27.10M | 154.60M | 152.60M | 142.40M |
| Net Income Ratio | -9.18% | 6.16% | 0.85% | -3.81% | -6.58% | 8.81% | 12.97% | 2.50% | -27.08% | 1.62% | 9.22% | 9.06% | 8.58% |
| EPS | -1.33 | 1.08 | 0.13 | -0.57 | -0.96 | 1.22 | 1.69 | 0.85 | -9.15 | 0.58 | 3.32 | 3.28 | 3.06 |
| EPS Diluted | -1.33 | 1.07 | 0.13 | -0.57 | -0.96 | 1.22 | 1.69 | 0.85 | -9.15 | 0.58 | 3.32 | 3.28 | 3.06 |
| Weighted Avg Shares Out | 46.60M | 46.90M | 48.10M | 47.80M | 47.60M | 47.20M | 46.52M | 46.60M | 46.59M | 46.54M | 46.51M | 46.51M | 46.51M |
| Weighted Avg Shares Out (Dil) | 46.60M | 47.30M | 48.60M | 47.80M | 47.60M | 47.20M | 46.80M | 47.00M | 46.59M | 46.54M | 46.51M | 46.51M | 46.51M |
3 Reasons to Add Avanos (AVNS) Stock to Your Portfolio
Avanos Medical, Inc. to Present at the 2023 Virtual KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
Should Value Investors Buy Avanos Medical (AVNS) Stock?
What Makes Avanos Medical (AVNS) a New Buy Stock
Avanos (AVNS) Q4 Earnings Surpass Estimates, Margins Up
Avanos Medical, Inc. (AVNS) Q4 2022 Earnings Call Transcript
Avanos Medical (AVNS) Q4 Earnings and Revenues Beat Estimates
Avanos Medical, Inc. to Webcast Conference Call Discussing Fourth Quarter and Full Year 2022 Financial Results
Avanos Medical, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference
3 Beaten-Down MedTech Stocks Poised for a Turnaround in 2023
Source: https://incomestatements.info
Category: Stock Reports